Day 16 September 2021

EMA and FDA launch pilot program for parallel scientific advice (PSA) for hybrid products and complex generic products

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established a pilot program to provide parallel scientific advice (PSA) to applicants of marketing authorisation applications (MAAs) for: hybrid products (EMA) and abbreviated new drug applications…